e-ISSN: Pending
Negative / Null Result ReportOpen accessImmunology and Microbiology· cited by 74

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients

Xiuli Zhang; S. Peter Goedegebuure; Michael Y. Chen; Rashmi Mishra; Felicia Zhang; Yafei Yu; Kartik Singhal; Lijin Li · 2024 · Genome Medicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II epitopes and performed a phase 1 clinical trial in triple-negative breast cancer patients with persistent disease on surgical pathology following neoadjuvant chemotherapy, a patient population at high risk of disease recurrence. METHODS: Expressed somatic mutations were identified by tumor/normal exome sequencing and tumor RNA sequencing. The pVACtools sof

Abstract by Xiuli Zhang; S. Peter Goedegebuure; Michael Y. Chen; Rashmi Mishra; Felicia Zhang; Yafei Yu; Kartik Singhal; Lijin Li, Genome Medicine (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/s13073-024-01388-3